
Lei Yao
Examiner (ID: 12775, Phone: (571)272-3112 , Office: P/1642 )
| Most Active Art Unit | 1642 |
| Art Unit(s) | 1642 |
| Total Applications | 1328 |
| Issued Applications | 662 |
| Pending Applications | 127 |
| Abandoned Applications | 552 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 12912631
[patent_doc_number] => 20180196053
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-07-12
[patent_title] => METHODS AND KITS FOR DETECTING CANCER
[patent_app_type] => utility
[patent_app_number] => 15/865727
[patent_app_country] => US
[patent_app_date] => 2018-01-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5574
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 54
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15865727
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/865727 | METHODS AND KITS FOR DETECTING CANCER | Jan 8, 2018 | Abandoned |
Array
(
[id] => 13413269
[patent_doc_number] => 20180258177
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-09-13
[patent_title] => ANTI-HUMAN 4-1BB ANTIBODIES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 15/863526
[patent_app_country] => US
[patent_app_date] => 2018-01-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32257
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15863526
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/863526 | Anti-human 4-1BB antibodies and uses thereof | Jan 4, 2018 | Issued |
Array
(
[id] => 12746599
[patent_doc_number] => 20180140700
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-05-24
[patent_title] => COMBINATION THERAPY WITH AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND A BCL-2 INHIBITOR
[patent_app_type] => utility
[patent_app_number] => 15/849018
[patent_app_country] => US
[patent_app_date] => 2017-12-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17124
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -39
[patent_words_short_claim] => 20
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15849018
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/849018 | Combination therapy with an anti-HER2 antibody-drug conjugate and a Bcl-2 inhibitor | Dec 19, 2017 | Issued |
Array
(
[id] => 13586631
[patent_doc_number] => 20180344864
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-12-06
[patent_title] => COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR
[patent_app_type] => utility
[patent_app_number] => 15/846083
[patent_app_country] => US
[patent_app_date] => 2017-12-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 70594
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15846083
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/846083 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR | Dec 17, 2017 | Abandoned |
Array
(
[id] => 12842548
[patent_doc_number] => 20180172689
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-06-21
[patent_title] => METHODS FOR DIAGNOSIS OF BLADDER CANCER
[patent_app_type] => utility
[patent_app_number] => 15/844828
[patent_app_country] => US
[patent_app_date] => 2017-12-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25172
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 128
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15844828
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/844828 | METHODS FOR DIAGNOSIS OF BLADDER CANCER | Dec 17, 2017 | Abandoned |
Array
(
[id] => 16337547
[patent_doc_number] => 10788496
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-09-29
[patent_title] => MEK1 mutation conferring resistance to RAF and MEK inhibitors
[patent_app_type] => utility
[patent_app_number] => 15/844236
[patent_app_country] => US
[patent_app_date] => 2017-12-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 6
[patent_no_of_words] => 28093
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 135
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15844236
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/844236 | MEK1 mutation conferring resistance to RAF and MEK inhibitors | Dec 14, 2017 | Issued |
Array
(
[id] => 13590097
[patent_doc_number] => 20180346597
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-12-06
[patent_title] => HUMAN MONOCLONAL ANTIBODIES TO GANGLIOSIDE GD2
[patent_app_type] => utility
[patent_app_number] => 15/839391
[patent_app_country] => US
[patent_app_date] => 2017-12-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27743
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 81
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15839391
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/839391 | Human monoclonal antibodies to ganglioside GD2 | Dec 11, 2017 | Issued |
Array
(
[id] => 17280877
[patent_doc_number] => 11197890
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-12-14
[patent_title] => Methods of treating cancer, infectious disease, and autoimmune disease using CXC chemokines
[patent_app_type] => utility
[patent_app_number] => 15/839105
[patent_app_country] => US
[patent_app_date] => 2017-12-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 48
[patent_figures_cnt] => 1
[patent_no_of_words] => 24841
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 58
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15839105
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/839105 | Methods of treating cancer, infectious disease, and autoimmune disease using CXC chemokines | Dec 11, 2017 | Issued |
Array
(
[id] => 12766375
[patent_doc_number] => 20180147293
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-05-31
[patent_title] => ANTIGEN BINDING PROTEINS
[patent_app_type] => utility
[patent_app_number] => 15/828770
[patent_app_country] => US
[patent_app_date] => 2017-12-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31887
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15828770
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/828770 | ANTIGEN BINDING PROTEINS | Nov 30, 2017 | Abandoned |
Array
(
[id] => 12880987
[patent_doc_number] => 20180185504
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-07-05
[patent_title] => METHODS OF TREATING PRLR POSITIVE BREAST CANCER
[patent_app_type] => utility
[patent_app_number] => 15/824546
[patent_app_country] => US
[patent_app_date] => 2017-11-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31723
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -54
[patent_words_short_claim] => 52
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15824546
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/824546 | Methods of treating PRLR positive breast cancer | Nov 27, 2017 | Issued |
Array
(
[id] => 17571120
[patent_doc_number] => 11319378
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-05-03
[patent_title] => Anti-PD-1/anti-HER2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same
[patent_app_type] => utility
[patent_app_number] => 16/461646
[patent_app_country] => US
[patent_app_date] => 2017-11-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 15
[patent_figures_cnt] => 17
[patent_no_of_words] => 10569
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 457
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16461646
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/461646 | Anti-PD-1/anti-HER2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same | Nov 15, 2017 | Issued |
Array
(
[id] => 12912634
[patent_doc_number] => 20180196054
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-07-12
[patent_title] => BIOMARKERS FOR OVARIAN CANCER CTAP3-RELATED PROTEINS
[patent_app_type] => utility
[patent_app_number] => 15/809591
[patent_app_country] => US
[patent_app_date] => 2017-11-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15423
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -2
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15809591
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/809591 | Biomarkers for ovarian cancer CTAP3-related proteins | Nov 9, 2017 | Issued |
Array
(
[id] => 12685462
[patent_doc_number] => 20180120320
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-05-03
[patent_title] => NOVEL METHOD FOR ANALYZING CIRCULATING TUMOR CELLS OF A PATIENT FOR THE PRESENCE OF METASTASIS-INITIATING CELLS
[patent_app_type] => utility
[patent_app_number] => 15/796647
[patent_app_country] => US
[patent_app_date] => 2017-10-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8892
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15796647
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/796647 | NOVEL METHOD FOR ANALYZING CIRCULATING TUMOR CELLS OF A PATIENT FOR THE PRESENCE OF METASTASIS-INITIATING CELLS | Oct 26, 2017 | Abandoned |
Array
(
[id] => 14007849
[patent_doc_number] => 10222376
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-03-05
[patent_title] => Methods and compositions for identifying leukemic stem cells
[patent_app_type] => utility
[patent_app_number] => 15/796201
[patent_app_country] => US
[patent_app_date] => 2017-10-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 9
[patent_no_of_words] => 12502
[patent_no_of_claims] => 2
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 270
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15796201
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/796201 | Methods and compositions for identifying leukemic stem cells | Oct 26, 2017 | Issued |
Array
(
[id] => 14210651
[patent_doc_number] => 20190117710
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-04-25
[patent_title] => METHODS FOR REGULATING ENDOGENOUS PRODUCTION OF CHECKPOINT PROTEINS
[patent_app_type] => utility
[patent_app_number] => 15/789266
[patent_app_country] => US
[patent_app_date] => 2017-10-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5404
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 41
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15789266
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/789266 | METHODS FOR REGULATING ENDOGENOUS PRODUCTION OF CHECKPOINT PROTEINS | Oct 19, 2017 | Abandoned |
Array
(
[id] => 16322343
[patent_doc_number] => 10782302
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-09-22
[patent_title] => Detectors of serum biomarkers for predicting ovarian cancer recurrence
[patent_app_type] => utility
[patent_app_number] => 15/785898
[patent_app_country] => US
[patent_app_date] => 2017-10-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 16
[patent_figures_cnt] => 32
[patent_no_of_words] => 22977
[patent_no_of_claims] => 2
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 90
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15785898
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/785898 | Detectors of serum biomarkers for predicting ovarian cancer recurrence | Oct 16, 2017 | Issued |
Array
(
[id] => 12624555
[patent_doc_number] => 20180100015
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-04-12
[patent_title] => COSTIMULATORY B7-H1 IN RENAL CELL CARCINOMA PATIENTS: INDICATOR OF TUMOR AGGRESSIVENESS AND POTENTIAL THERAPEUTIC TARGET
[patent_app_type] => utility
[patent_app_number] => 15/719750
[patent_app_country] => US
[patent_app_date] => 2017-09-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11755
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15719750
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/719750 | COSTIMULATORY B7-H1 IN RENAL CELL CARCINOMA PATIENTS: INDICATOR OF TUMOR AGGRESSIVENESS AND POTENTIAL THERAPEUTIC TARGET | Sep 28, 2017 | Abandoned |
Array
(
[id] => 16549769
[patent_doc_number] => 10882918
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-01-05
[patent_title] => Bispecific T cell activating antigen binding molecules
[patent_app_type] => utility
[patent_app_number] => 15/718818
[patent_app_country] => US
[patent_app_date] => 2017-09-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 27
[patent_figures_cnt] => 20
[patent_no_of_words] => 50092
[patent_no_of_claims] => 33
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 186
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15718818
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/718818 | Bispecific T cell activating antigen binding molecules | Sep 27, 2017 | Issued |
Array
(
[id] => 17268517
[patent_doc_number] => 11193937
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-12-07
[patent_title] => Immunohistochemical assay for detecting expression of programmed death ligand 1 (PD-L1) in tumor tissue
[patent_app_type] => utility
[patent_app_number] => 15/712246
[patent_app_country] => US
[patent_app_date] => 2017-09-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 22
[patent_no_of_words] => 15040
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 376
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15712246
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/712246 | Immunohistochemical assay for detecting expression of programmed death ligand 1 (PD-L1) in tumor tissue | Sep 21, 2017 | Issued |
Array
(
[id] => 18765120
[patent_doc_number] => 11815516
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-11-14
[patent_title] => Protein biomarkers for diseases associated with the contact activation system
[patent_app_type] => utility
[patent_app_number] => 16/333155
[patent_app_country] => US
[patent_app_date] => 2017-09-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 10
[patent_no_of_words] => 16470
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 122
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16333155
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/333155 | Protein biomarkers for diseases associated with the contact activation system | Sep 14, 2017 | Issued |